Source comparison
BPC-157 GHK-Cu Stack Protocol: Dosing Comparison
Research applications for the BPC-157 GHK-Cu stack protocol vary significantly based on study objectives, tissue type under investigation, and whether the model examines acute injury or chronic degeneration. The table below compares three common dosing framewo
This comparison does not assign a generated winner or score.
- Research applications for the BPC-157 GHK-Cu stack protocol vary significantly based on study objectives, tissue type under investigation, and whether the model examines acute injury or chronic degeneration. The table below compares three common dosing frameworks used in published peptide research.
- Standard Tissue Repair
- 250–500 mcg/day
- 1–2 mg/day
- Twice daily (BPC-157), once daily (GHK-Cu)
- Acute soft tissue injury, post-surgical healing models
- Most evidence-supported dosing range; used in 60%+ of published BPC-157 studies
- High-Intensity Regenerative
- 500–750 mcg/day
- 2–3 mg/day
- Twice daily (both peptides)
- Severe ligament tears, chronic tendinopathy, degenerative joint models
- Higher doses show diminishing returns above 500 mcg BPC-157 in some models; copper toxicity risk above 3 mg GHK-Cu
- Topical + Subcutaneous Hybrid
- 250–500 mcg/day (subQ)
- 1–2 mg/day (topical), 0.5–1 mg/day (subQ)
- Once daily subQ, twice daily topical
- Dermal wound healing, burn models, cosmetic tissue remodeling studies
- Topical GHK-Cu avoids systemic copper load; subQ BPC-157 maintains angiogenic signaling
- The standard tissue repair protocol represents the most commonly replicated framework in peer-reviewed research and offers the best balance between therapeutic effect and peptide cost-efficiency. High-intensity protocols appear in late-stage degenerative models but lack sufficient evidence to justify routine use. Topical GHK-Cu administration is particularly effective in dermal studies where copper ion delivery directly to the wound site reduces systemic exposure and maintains higher local concentrations.